INTERVENTION OF RECOMBINANT HUMAN ENDOSTATIN COMBINED WITH IRESSA CAN REDUCE TOXIC SIDE EFFECTS AND IMPROVE SURVIVAL RATE IN PATIENTS WHO HAVE FAILED CHEMOTHERAPY FOR NON-SMALL CELL LUNG CANCER

Huang Shulin^*, Sun Cheng, Pan Weihong, Yang Haiyu, Lv Qiang, Zhu Wenjuan

Department of Oncology, Zibo Bashan Wanjie Hospital, Zibo, 255213, China

Objective: To study the effect of recombinant human endostatin (rh-ES) combined with iressa intervention on the toxic side effects and survival rate of patients who have failed chemotherapy for non-small cell lung cancer (NSCLC).

Methods: 82 NSCLC patients who failed first-line or second-line chemotherapy in our hospital from February 2014 to March 2016 were collected as the research subject, of which 38 cases were treated with iressa as the control group (CG) and 44 patients were treated with rh-ES combined with iressa as the observation group (OG). The expression levels of CEA and VEGF in serum, occurrence of toxic side effects, clinical efficacy and 3-year survival of patients were observed in the two groups. Cox regression analysis was applied to analyze the prognostic factors of the patients.

Results: Before treatment, there was no significant difference in CEA and VEGF expression between the two groups. After treatment, the expression levels of CEA and VEGF were obviously reduced in both groups, and the expression levels of CEA and VEGF in OG were obviously lower than those in CG. The incidence of toxic side effects in OG was obviously lower than that in CG. The objective response rate, treatment effective rate and 3-year survival rate in OG were obviously higher than those in CG. Cox regression analysis showed that ECOG score, TNM stages, CEA level, VEGF level and treatment plan were independent prognostic factors affecting patients.

Conclusion: Iressa combined with rh-ES intervention can reduce toxic side effects and improve survival rate in patients who have failed chemotherapy for NSCLC, which is worthy of clinical promotion.